Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 4/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652504 | 0.88 | KDM4E (0.43) | KDM4ETDP1GCGRGIPRPPARG | |
| SCHEMBL2652219 | 0.87 | GCGR (0.50) | GCGRCYP1A2GIPRENPP2VIPR2 | |
| SCHEMBL2653039 | 0.86 | MRGPRX1 (0.51) | GCGRPPARG | |
| SCHEMBL2651576 | 0.86 | EGLN1 (0.48) | GCGRPPARG | |
| SCHEMBL2651903 | 0.81 | HDAC1 (0.41) | KDM4ETDP1GCGRGIPR | |
| SCHEMBL7116449 | 0.81 | GCGR (0.50) | GCGRGIPRPPARG | |
| SCHEMBL7113992 | 0.80 | SMN1; SMN2 (0.43) | GCGRALDH1A1HPGDPPARG | |
| SCHEMBL2651501 | 0.80 | GCGR (0.43) | KDM4EGCGRALDH1A1PPARG | |
| SCHEMBL2655061 | 0.79 | PTGDR2 (0.46) | KDM4EALDH1A1PPARG | |
| SCHEMBL2652045 | 0.79 | ENPP2 (0.51) | KDM4EALDH1A1HPGDCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | KDM4E 3680/4885TDP1 4805/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.